Strong Profit MarginsSustained high gross and healthy operating margins indicate durable pricing power and efficient cost structure. These margins provide long-term earnings resilience against input cost swings, support reinvestment in R&D or commercialization, and underpin consistent profitability over multiple quarters.

Low Financial LeverageA low debt-to-equity ratio signals limited leverage and financial flexibility. This reduces refinancing and default risk, preserves capacity to fund development or acquisitions without distress, and provides a stable capital base to support multi-quarter operational plans and strategic investments.

Good Operating Cash ConversionOCF-to-net-income >1 indicates quality of earnings and effective cash generation from core operations. Durable cash conversion supports funding of recurring expenditures, working capital needs and selective investments without immediate reliance on external funding, enhancing operational stability.

Bears Say

Negative Free Cash FlowNegative free cash flow erodes internal funding for growth and can force reliance on external financing or equity issuance. Over several quarters this pressures strategic flexibility, may constrain R&D or commercialization spend, and increases sensitivity to capital market conditions.

Sharp EPS DeclineA steep drop in EPS signals material earnings volatility or one-off impacts that reduce per-share profitability. Persisting EPS weakness can limit internal reinvestment, reduce investor confidence in earnings sustainability, and magnify the effect of revenue or margin headwinds over time.

Moderate Return On EquityROE in the mid-teens suggests the company currently achieves only moderate returns on shareholder capital versus higher-growth biotech peers. Without improvement, this can limit long-term shareholder value creation and may indicate opportunities to better leverage assets or improve capital allocation.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

7M ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥744.00 and its highest was ¥1462.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥8.96B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is May 07, 2026 which is in 80 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on Feb 12, 2026. The company reported ¥6.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥6.12.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥6.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.296%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.